You are here

Novartis

Novartis inks $925M Anthos takeover to buy back phase 3 clot-busting candidate

Fierce Biotech

Tue, 02/11/25 - 11:42 am

Anthos Therapeutics

How pharma and health ads performed at Super Bowl LIX

Medical Marketing and Media

Tue, 02/11/25 - 11:16 am

DTC advertising

Hims & Hers Health

With uncertainty roiling Big Pharma, execs are placing lower-risk bets

Pharma Voice

Fri, 02/7/25 - 11:16 am

Pfizer taps a former Novartis exec to lead cancer drug push

BioPharma Dive

Thu, 02/6/25 - 11:38 am

Novartis gives up on anti-CD40 antibody to treat Sjögren's due to 'benefit/risk profile'

Fierce Biotech

Fri, 01/31/25 - 11:14 am

Sjögren’s syndrome

Swiss pharma giant Novartis posts better-than-expected fourth-quarter sales

CNBC

Fri, 01/31/25 - 11:13 am

Novartis to Make Super Bowl 2025 Debut with Breast Cancer Commercial

Xtalks

Thu, 01/30/25 - 11:24 pm

DTC advertising

After an obesity stumble, BioAge reconnects with its longevity pipeline

Pharma Voice

Wed, 01/22/25 - 11:20 am

Novartis's U.S. patent for Entresto upheld by appeals court

Marketscreener

Mon, 01/13/25 - 05:45 pm

Broader population could benefit from Novartis spinal muscular atrophy treatment

Clinical Trials Arena

Mon, 01/13/25 - 05:39 pm

Light Horse lassos Novartis partnership worth up to $1B, wrangles $62M series A

Fierce Biotech

Thu, 01/9/25 - 09:29 pm

Light Horse Therapeutics

genetic screening

Positive data could expand use of Novartis’ gene therapy for SMA

Clinical Trials Arena

Fri, 01/3/25 - 11:02 am

Novartis’ Phase III spinal muscular atrophy therapy trial meets primary endpoint

Clinical Trials Arena

Thu, 01/2/25 - 11:25 am

clinical trials

spinal muscular atrophy

Novartis to shutter 2 MorphoSys sites, lay off 330 staffers in post-buyout consolidation

Fierce Pharma

Thu, 12/19/24 - 10:11 am

UCB's orchestra hits dud note: Novartis-partnered Parkinson's asset fails phase 2

Fierce Biotech

Tue, 12/17/24 - 11:58 am

Parkinson's Disease

clinical trials

ICER calls out Gilead, J&J, Novartis and more in latest report on 'unsupported' price increases

Fierce Pharma

Thu, 12/12/24 - 11:44 pm

Gilead Sciences

Can CAR-T first movers keep pace in a rapidly evolving market?

Pharmaphorum

Wed, 12/11/24 - 10:59 am

Gilead Sciences

Novartis reports topline outcomes from Phase IIIB PNH trial of Fabhalta

Clinical Trials Arena

Mon, 12/9/24 - 10:41 am

clinical trials

Novartis bid to block generic Entresto in US suffers setback

Pharmaphorum

Thu, 12/5/24 - 11:01 am

Novartis wagers billions of dollars on PTC Huntington’s drug

BioPharma Dive

Mon, 12/2/24 - 11:26 am

PTC Therapeutics

Huntington's disease

Pages